Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Patients | Phase | Treatment | n | OS (m) | PFS (m) | RR |
Advanced HER-positive gastric cancer as first line (TOGA) | III | 5-FU + cisplatin or capecitabine + cisplatin | 290 | 11.1 | 5.5 | 34.5% |
5-FU + cisplatin + trastuzumab or capecitabine + cisplatin + trastuzumab | 294 | 13.8 | 6.7 | 47.3% |
- Citation: Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755
- URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13741.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13741